The US is the best place for a business to invest, the boss of one of the UK’s biggest pharmaceutical companies has said.
Dame Emma Walmsley, chief executive of vaccines and medicines giant GSK, said it will invest $30bn (£23bn) in the US by 2030.
It comes as other major drug makers have pulled UK projects worth billions after years of frustration on NHS drug budgets and pressure from President Donald Trump to set up production in the US.
However, Dame Emma, who will leave GSK in January after eight years in charge, welcomed a new deal which will see the NHS pay more to help secure zero tariffs on shipping UK pharmaceuticals to America.
Speaking to the BBC from the firm’s central London headquarters, Dame Emma said she would not “shy away” from GSK’s investment plans for the US, where it makes more than half of its turnover.
Dispatches From The Front 